EFFECTS OF A MEDICATION MANAGEMENT REVIEW SERVICE ON PATIENTS DIAGNOSED WITH TYPE II DIABETES: A RANDOMIZED CONTROLLED TRIAL

Abstract

A medication management review (MMR) optimizes the patients' therapeutic outcomes. Jordan has the world's highest prevalence of type II diabetes. This study's purpose was to explore the effectiveness of the MMR service on patients with type Π diabetes. This is the first randomized controlled MMR study conducted in the Middle East that concentrates on patients with diabetes type Π only. 139 patients were approached and randomly selected from three healthcare centers in Ajloun, Jordan. Patients were divided into experimental (n = 70) and control (n = 69). All participants were re-evaluated after three months of MMR service. 407 treatment-related problems (TRPs) were identified. The mean number of TRPs was (2.92 ± 0.95) per patient. After three months, there was a significant decrease in the average number of TRPs in the experimental group, from 3.02 ± 0.95 to 0.5 ± 0.62 per patient, p < 0.0001. Also, there was a significant decrease in the mean of HbA1c from 7.80 to 7.31 (p < 0.01). The mean of self-care activity improved from 27.22 to 35.85 (p < 0.001), where the drug adherence improved as the mean score decreased from 12.95 to 10.38 (p < 0.001) and the quality of life improved as the mean score decreased from 29.60 to 26.01 (p < 0.001). More than 88.20% of the TRPs were resolved in the intervention group. Clinical pharmacist advice was well-received by physicians (67.53% acceptance rate). This study demonstrated that Jordan needs MMR for type II patients with diabetes. The service was well accepted and can be implemented following the policymaker's approval.